Anastrozole: as the comparator
42 studies: what is tested is compared with it. Page 1 of 1. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.
- A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast CancerNot yet recruitingNCT07894328Phase 3How we knowReport a problem
- A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast CancerRecruitingNCT07349069Phase 3How we knowReport a problem
- Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)RecruitingNCT07190443Phase 3How we knowReport a problem
- A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast CancerRecruitingNCT07024173Phase 3How we knowReport a problem
- Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeRecruitingNCT06486883Phase 2How we knowReport a problem
- Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical TrialRecruitingNCT06176534Phase 2How we knowReport a problem
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerRecruitingNCT06072781Phase 3How we knowReport a problem
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyRecruitingNCT05774951Phase 3How we knowReport a problem
- Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)RecruitingNCT05512364Phase 3How we knowReport a problem
- Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After LumpectomyRecruitingNCT05472792Phase 2How we knowReport a problem
- A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerRecruitingNCT04985266Phase 2How we knowReport a problem
- A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to SurgeryCompletedNCT05549505Phase 2Results postedHow we knowReport a problem
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)CompletedNCT04436744Phase 2Results postedHow we knowReport a problem
- Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT StudyTerminatedNCT04256941Phase 2Results postedHow we knowReport a problem
- Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast CancerTerminatedNCT04059484Phase 2Results postedHow we knowReport a problem
- Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerCompletedNCT03778931Phase 3Results postedHow we knowReport a problem
- A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.CompletedNCT01602380Phase 3Results postedHow we knowReport a problem
- Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast CancerCompletedNCT00871858Phase 2Results postedHow we knowReport a problem
- A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast CancerCompletedNCT00274469Phase 2Results postedHow we knowReport a problem
- Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast CancerCompletedNCT00248170Phase 3Results postedHow we knowReport a problem
- Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast CancerCompletedNCT00143390Phase 3Results postedHow we knowReport a problem
- Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast CancerCompletedNCT00066573Phase 3Results postedHow we knowReport a problem
- Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialSuspendedNCT06671912Phase 3How we knowReport a problem
- A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast CancerWithdrawnNCT06585969Phase 3How we knowReport a problem
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceActive, not recruitingNCT06492616Phase 3How we knowReport a problem
- OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerActive, not recruitingNCT06016738Phase 3How we knowReport a problem
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Active, not recruitingNCT05952557Phase 3How we knowReport a problem
- A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast CancerCompletedNCT05896566Phase 2How we knowReport a problem
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerActive, not recruitingNCT05514054Phase 3How we knowReport a problem
- Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)Active, not recruitingNCT04964934Phase 3How we knowReport a problem
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Active, not recruitingNCT04961996Phase 3How we knowReport a problem
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseActive, not recruitingNCT04711252Phase 3How we knowReport a problem
- Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Volunteers Under Fed ConditionStatus unknownNCT04445922Phase 1How we knowReport a problem
- Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Volunteers Under Fasted ConditionStatus unknownNCT04438733Phase 1How we knowReport a problem
- ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast CancerActive, not recruitingNCT04134598Phase 3How we knowReport a problem
- PAlbociclib and Circulating Tumor DNA for ESR1 Mutation DetectionCompletedNCT03079011Phase 3How we knowReport a problem
- A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast CancerStatus unknownNCT03024580Phase 2How we knowReport a problem
- The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast CancerStatus unknownNCT02072512Phase 2How we knowReport a problem
- Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast CancerWithdrawnNCT01814865Phase 2How we knowReport a problem
- Bioequivalence Study Comparing Arimidex Tablet and Anastrozole ODF in Japanese Healthy Male SubjectsCompletedNCT01568281Phase 1How we knowReport a problem
- Second Line Breast Cancer TrialCompletedNCT00635713Phase 3How we knowReport a problem
- Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer PatientsCompletedNCT00128843Phase 2How we knowReport a problem